methyl 4-deoxy-β-L-erythro-pentopyranoside | 58990-26-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: methyl 4-deoxy-β-L-erythro-pentopyranoside
• 英文别名: methyl-(β-L-erythro-4-deoxy-pentopyranoside)；Methyl-(β-L-erythro-4-desoxy-pentopyranosid)；Qvnptepowbeitr-zluobgjfsa-；(2S,3S,4S)-2-methoxyoxane-3,4-diol
• CAS: 58990-26-4
• 化学式: C₆H₁₂O₄
• 分子量: 148.159
• InChiKey: QVNPTEPOWBEITR-ZLUOBGJFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.92
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  methyl 4-deoxy-β-L-erythro-pentopyranoside 在 硫酸 作用下， 生成 L-erythro-4-deoxy-pentose
  参考文献：
  名称：

  84.由D-lyxose合成4-deoxy-L-核糖

  摘要：

  DOI：

  10.1039/jr9530000416
• 作为产物：
  描述：

  di-O-benzoyl-2,3 desoxy-4 β-D,L-erythro-pentopyranoside de methyle 在 Alkaline 作用下， 生成 methyl 4-deoxy-β-L-erythro-pentopyranoside
  参考文献：
  名称：

  Ouverture d'epoxydes par des acides organiques dans L'H.M.P.T.: nouvelle voie d'acces a des desoxypentopyranosides

  摘要：

  DOI：

  10.1016/s0040-4039(01)93030-8

文献信息

• [EN] MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS<br/>[FR] ALGINATES MODIFIÉS POUR MATÉRIAUX ANTI-FIBROTIQUES ET APPLICATIONS ASSOCIÉES
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2017075631A1

  公开（公告）日：2017-05-04

  Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

  本文揭示了具有增强生物相容性和定制物理化学性质的共价修饰海藻酸盐聚合物，以及其制备和使用方法。共价修饰的海藻酸盐可用作任何需要减少纤维化的材料的涂层基质，例如用于移植的包埋细胞和植入或在体内使用的医疗器械。
• Fluorine-containing anthracycline derivatives having hydroxyl groups(s)
  申请人：Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

  公开号：US05789386A1

  公开（公告）日：1998-08-04

  To provide novel fluorine-containing anthracycline derivatives having high antitumor activities and a solubility in water, there have now been synthesized a 7-O-(2,6-dideoxy-2-fluoro-3-O- or -4-O- or -3,4-di-O-aminoalkanoyl-.alpha.-L-talopyranosyl)daunomycinone or -adriamycinone of general formula (I) shown below, as well as a 7-O-(3-O- or -4-O- or -3,4-di-O-aminoalkanoyl-2,6-dideoxy-2,6,6,6-tetrafluoro-.alpha.-L-talopyra nosyl- or -2,6-dideoxy-6,6,6-trifluoro-.alpha.-L-lyxo-hexopyranosyl)adriamycinone of general formula (II) shown below: General formula (I) ##STR1## General formula (II) ##STR2## wherein either one or both of A.sup.1 and A.sup.2 is or are an .alpha.-amino acid residue or an .omega.-amino acid residue and T denotes a fluorine or hydrogen atom. The novel fluorine-containing anthracycline derivatives of general formulae (I) and (II) are highly active against tumors and soluble in water, and they are useful as antitumor agents administrable in the form of injectable solution.

  为了提供具有高抗肿瘤活性和水溶性的新型含氟蒽环素衍生物，已合成了如下所示的通用式(I)的7-O-(2,6-二去氧-2-氟-3-O-或-4-O-或-3,4-二-O-氨基烷酰-α-L-戊糖苷)多柔比星醌或阿霉素醌，以及如下所示的通用式(II)的7-O-(3-O-或-4-O-或-3,4-二-O-氨基烷酰-2,6-二去氧-2,6,6,6-四氟-α-L-戊糖苷-或-2,6-二去氧-6,6,6-三氟-α-L-利克糖苷)阿霉素醌：通用式(I) ##STR1## 通用式(II) ##STR2## 其中A^1和A^2中的一个或两个是α-氨基酸残基或ω-氨基酸残基，T表示氟或氢原子。通用式(I)和(II)的新型含氟蒽环素衍生物对肿瘤具有很高的活性，并且在水中溶解，它们可作为抗肿瘤剂以注射溶液的形式使用。
• A 5‘-(Trifluoromethyl)anthracycline Glycoside:  Synthesis of Antitumor-Active 7-<i>O</i>-(2,6-Dideoxy-6,6,6-trifluoro-α-<scp>l</scp>-<i>lyxo</i>-hexopyranosyl)adriamycinone
  作者：Yasushi Takagi、Ken Nakai、Tsutomu Tsuchiya、Tomio Takeuchi

  DOI：10.1021/jm960177x

  日期：1996.1.1

  7-O-(2,6-Dideoxy-6,6,6-trifluoro-alpha-L-lyxo-hexopyranosyl)adriam ycinone (3), whose substituent at C-5' is a lipophilic trifluoromethyl group, has been prepared by coupling of 3,4-di-O-acetyl-2,6-dideoxy-6,6,6-trifluoro-alpha-L-lyxo-hexopyran osyl bromide (20) with 14-O-(tert-butyldimethylsilyl)adriamycinone under the Koenigs-Knorr conditions. The key step in this synthesis was the C-trifluoromethylation

  已经通过以下方法制备了7-O-（2,6-二脱氧-6,6,6-三氟-α-L-lyxo-己吡喃糖基）阿德里亚姆（3），其在C-5'的取代基是亲脂性三氟甲基。 3,4-二-O-乙酰基-2,6-二脱氧-6,6,6-三氟-α-L-lyxo-己吡喃糖基溴化物（20）与14-O-（叔丁基二甲基甲硅烷基）去甲霉素的偶合Koenigs-Knorr条件。该合成过程中的关键步骤是10中衍生自D-lyxose的5-O-乙酰基-2,3-二-O-苄基-4-脱氧醛-L-赤型戊糖的C-三氟甲基化（10）步骤，在四丁基氟化铵存在下，用（三氟甲基）三甲基硅烷，得到1,1,1-三氟-L-阿拉伯糖基己糖醇（11）及其2-表异构体。与包括阿霉素的类似物相比，合成产物3在低剂量范围内显示出显着的体内抗肿瘤活性。
• NOVEL ANTHRACYCLINE DERIVATIVES CONTAINING TRIFLUOROMETHYLATED SUGAR UNIT
  申请人：ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI

  公开号：EP0749976A1

  公开（公告）日：1996-12-27

  Novel anthracycline derivatives have now been produced, which exhibit higher antitumor activities and lower toxicities than those of daunomycin, adriamycin etc. that have been clinically used as anticancer agents. That is, a daunomycinone or adriamycinone derivative represented by the general formula (I): wherein R is a hydrogen atom or a hydroxyl group, and 7-O-(2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone derivative which is an adriamycinone derivative represented by formula (II): have now been newly synthesized. The novel anthracycline derivatives having the general formula (I) and formula (II), respectively, show excellent anticancer or antitumor activities and are of low toxicities. These novel compounds are very useful as anticancer or antitumor agents and are expected to be useful for the therapeutic treatments of a variety of cancers and tumors, similarly to daunomycin or adriamycin.

  目前已生产出新型蒽环类衍生物，与临床上用作抗癌剂的达霉素、阿霉素等相比，它们具有更高的抗肿瘤活性和更低的毒性。即由通式（I）代表的达霉素酮或阿霉素酮衍生物： 其中 R 是氢原子或羟基，7-O-(2,6-二脱氧-6,6,6-三氟-α-L-来苏己吡喃糖基)阿霉素酮衍生物是由式（II）表示的阿霉素酮衍生物： 的阿霉素衍生物。 分别具有通式(I)和式(II)的新型蒽环类衍生物显示出卓越的抗癌或抗肿瘤活性，而且毒性低。这些新型化合物作为抗癌剂或抗肿瘤剂非常有用，有望与达霉素或阿霉素类似，用于各种癌症和肿瘤的治疗。
• Fluorine-containing anthracycline derivatives having hydroxyl group(s) mono- or di-o-aminoalkanoylated in the sugar moiety thereof
  申请人：ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI

  公开号：EP0761678A1

  公开（公告）日：1997-03-12

  To provide novel fluorine-containing anthracycline derivatives having high antitumor activities and a solubility in water, there have now been synthesized a 7-O-(2,6-dideoxy-2-fluoro-3-O- or -4-O- or -3,4-di-O-aminoalkanoyl-α-L-talopyranosyl)daunomycinone or -adriamycinone of general formula (I) shown below, as well as a 7-O-(3-O- or -4-O-or -3,4-di-O-aminoalkanoyl-2,6-dideoxy-2,6,6,6-tetrafluoro-α-L-talopyranosyl- or -2,6-dideoxy-6,6,6-trifluoro-α-L-lyxo-hexopyranosyl)adriamycinone of general formula (II) shown below:- wherein either one or both of A1 and A2 is or are an α-amino acid residue or an ω-amino acid residue and T denotes a fluorine or hydrogen atom. The novel fluorine-containing anthracycline derivatives of general formulae (I) and (II) are highly active against tumors and soluble in water, and they are useful as antitumor agents administrable in the form of injectable solution.

  为了提供具有高抗肿瘤活性和水溶性的新型含氟蒽环类衍生物，现已合成了通式(I)如下的7-O-(2,6-二脱氧-2-氟-3-O-或-4-O-或-3,4-二-O-氨基烷酰基-α-L-吡喃甘露糖基)daunomycinone或-adriamycinone、以及下表所示通式(II)的 7-O-(3-O-或-4-O-或-3,4-二-O-氨基烷酰基-2,6-二脱氧-2,6,6,6-四氟-α-L-吡喃他酰胺基-或-2,6-二脱氧-6,6,6-三氟-α-L-来苏己吡喃糖基)阿霉素酮：- 其中 A1 和 A2 中的一个或两个是 α-氨基酸残基或 ω-氨基酸残基，T 表示氟原子或氢原子。通式(I)和(II)的新型含氟蒽环类衍生物具有很强的抗肿瘤活性，可溶于水，可作为抗肿瘤药物以注射液的形式给药。